The standard treatment of adenoid cystic carcinoma (ACC) of the airway is surgery if possible, since survival rate is better than other treatments including radiotherapy. Although ACC shows frequent recurrence during the long term follow up unless there has been a complete resection (negative surgical margin), no further treatments are recommended. This report describes how argon plasma coagulation using flexible bronchoscopy has been successfully employed in the treatment of ACC after conventional therapy in one case of recurrence after surgery and two cases of inoperable patients. All of the patients are alive and healthy more than six years after diagnosis.
Introduction
Adenoid cystic carcinoma (ACC) of the airway is a rare primary tumor that occurs in all adult age groups and is frequently slow to progress and late to metastasize or recur locally [1] . Although tumors of the trachea are much less common than those found in the lungs, squamous cell carcinoma and ACC are the most frequent histological types [2] . These lesions are usually resistant to nonsurgical therapy especially to chemotherapy. Many cases are open to a segmental resection of the airway with removal of all gross disease and reconstruction by primary anastomosis [1] . Gaissert et al. has reported relatively good results in 101 resected lesions in a total of 135 patients with ACC [2] . However, not all patients could undergo surgery because of a delay in diagnosis, the propensity of the tumor to spread submucosally and along perineural bundles and the difficulty of resection due to the length limit (up to 6 cm) [1] [2] [3] . Furthermore, a high rate of recurrence and incomplete resection has been reported [1, 2] . Palliative therapy for airway management was required for those patients. The use of lasers for treating tracheobronchial ACC has been reported [3, 4] , however standard the palliative therapeutic strategy is not presented due to the low incidence of this disease.
Argon plasma coagulation (APC) has recently been widely used in tracheobronchial disease [5, 6] because it allows a rapid coagulation with minimal manipulation and mechanical trauma to the target tissue [6] . A previous study reported the safety efficacy of APC for the management of airway stenosis [7] .
APC was also used for the management of recurrent three cases of ACC after several treatments, including tracheal reconstruction, radiation and brachytherapy etc. This report will discuss the safety and usefulness of this therapy for palliative airway management. Table 1 shows clinical details and follow-up of our cases.
Case Report

Case 1
A 48-year-old male was admitted to the hospital for hemosputum in January 1999. (Figure 1A,   B) . The APC procedure was performed every one to two months (total 7times). No adverse effects have occurred and she is now able to lead a normal life as a housewife.
Discussion
This study describes the use of APC against ACC after standard therapies have been unsuccessful. The APC provided keep tracheobronchial patency in patients with recurrent ACC after either reconstructive surgery or when surgery was considered impossible.
Longer survival has been reported in patients that underwent a resection for ACC than those who did not [2] . The largest study of ACC (135 cases) indicated a significant survival benefit associated with complete resection and negative airway margins [2] . The radiosensitivity of cervico-cranial ACC has been demonstrated [8] .
In addition, radiotherapy of tracheobronchial ACC is also recommended especially when a positive margin is observed after surgery and for palliative therapy [3] .
However, recurrence will inevitably occur after these established therapies.
Considering the pathophysiological characteristics of this disease, further palliative therapy for maintaining airway patency must be applied. Nd-YAG laser photoresection is the most common strategy for palliative treatment in unresected and recurrent ACC [4, 9] . Patients who received laser therapy experience immediate symptomatic relief and relatively good results for palliative therapy [2, 4, 9] .
However, Nd-YAG laser photoresection usually requires a rigid bronchoscope and general anesthesia, and fatal adverse effects such as hemorrhage have been reported during and after this therapy [9] . For these reasons, repetitive treatment for keeping airway patency seems somewhat difficult in most therapeutic units.
Recently, APC has been used in the treatment of benign or malignant lesions in the airway [5] [6] [7] . It has an excellent safety profile, is convenient and simple to use, and is relatively inexpensive. These characteristics make it suitable for therapeutic applications through a flexible bronchoscope [6] . Morice et al. [6] showed that APC devitalizes tissue gradually by producing temperatures that coagulate and desiccate tissue. This can result in a homogenous but limited depth of penetration (approximately 3 mm). As a result, APC offers uniform coagulation and good protection against airway perforation and hemorrhage [6] . No adverse events occurred during the 59 treatment courses in the three cases described in this report.
In addition, no patients required oxygen supplementation during the therapeutic periods in this series.
This report documents the use of APC against ACC in only three cases, therefore, there is no available data about the prognosis. However, all these cases have maintained good performance status for more than 6 years. Because the largest series addressing ACC treatment [2] reported that the overall 5-and 10-year survival in resectable and unresectable ACC were 52% and 33%, this palliative airway management strategy appears to be effective.
In summary, repetitive endobronchial dilatation was performed using APC in three cases of ACC after standard therapies had been insufficient. APC was able to provide a further palliative therapeutic choice for maintaining airway patency in patients with recurrent tracheobronchial ACC. 
Figure legends
